Home/Filings/4/0001213900-20-023272
4//SEC Filing

Liatos John 4

Accession 0001213900-20-023272

CIK 0001498382other

Filed

Aug 20, 8:00 PM ET

Accepted

Aug 21, 4:17 PM ET

Size

5.3 KB

Accession

0001213900-20-023272

Insider Transaction Report

Form 4
Period: 2020-08-19
Liatos John
DirectorSVP, Business Development
Transactions
  • Purchase

    Common Stock

    2020-08-19+196,750196,750 total
Footnotes (1)
  • [F1]Received in exchange for 125,000 shares of Adgero Biopharmaceuticals Holdings, Inc. ("Adgero") common stock, par value $0.0001 per share, in connection with the completion of the merger (the "Merger"), on August 19, 2020 (the "Effective Date"), of Adgero Acquisition Corp., a subsidiary of the Issuer, with and into Adgero, pursuant to the Agreement and Plan of Merger and Reorganization, dated as of June 9, 2020. On the Effective Date, each share of Adgero common stock was converted automatically into the right to receive 1.5740 shares of the Issuer's common stock, par value $0.001 per share.

Documents

1 file

Issuer

Kintara Therapeutics, Inc.

CIK 0001498382

Entity typeother

Related Parties

1
  • filerCIK 0001821508

Filing Metadata

Form type
4
Filed
Aug 20, 8:00 PM ET
Accepted
Aug 21, 4:17 PM ET
Size
5.3 KB